|
|
|
|||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
This article has been cited by other articles:
![]() |
A. Gopalakrishnan, M. Sievert, and A. E. Ruoho Identification of the Substrate Binding Region of Vesicular Monoamine Transporter-2 (VMAT-2) Using Iodoaminoflisopolol as a Novel Photoprobe Mol. Pharmacol., December 1, 2007; 72(6): 1567 - 1575. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Murase and R. D. McKay A specific survival response in dopamine neurons at most risk in Parkinson's disease. J. Neurosci., September 20, 2006; 26(38): 9750 - 9760. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Wimalasena and K. Wimalasena Kinetic Evidence for Channeling of Dopamine between Monoamine Transporter and Membranous Dopamine-{beta}-monooxygenase in Chromaffin Granule Ghosts J. Biol. Chem., April 9, 2004; 279(15): 15298 - 15304. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Machado, J. F. Gomez, G. Betancor, M. Camacho, M. A. Brioso, and R. Borges Hydralazine Reduces the Quantal Size of Secretory Events by Displacement of Catecholamines From Adrenomedullary Chromaffin Secretory Vesicles Circ. Res., November 1, 2002; 91(9): 830 - 836. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Machado, A. Morales, J. F. Gomez, and R. Borges cAMP Modulates Exocytotic Kinetics and Increases Quantal Size in Chromaffin Cells Mol. Pharmacol., September 1, 2001; 60(3): 514 - 520. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gerhard, N. Neumayer, E. Presecan-Siedel, R. Zanner, E. Lengyel, T. Cramer, M. Hocker, and C. Prinz Gastrin Induces Expression and Promoter Activity of the Vesicular Monoamine Transporter Subtype 2 Endocrinology, August 1, 2001; 142(8): 3663 - 3672. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. EIDEN The vesicular neurotransmitter transporters: current perspectives and future prospects FASEB J, December 1, 2000; 14(15): 2396 - 2400. [Full Text] |
||||
![]() |
G. R. UHL, S. LI, N. TAKAHASHI, K. ITOKAWA, Z. LIN, M. HAZAMA, and I. SORA The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins FASEB J, December 1, 2000; 14(15): 2459 - 2465. [Abstract] [Full Text] |
||||
![]() |
W. Y. Lee, J. W. Chang, N. L. Nemeth, and U. J. Kang Vesicular Monoamine Transporter-2 and Aromatic L-Amino Acid Decarboxylase Enhance Dopamine Delivery after L-3,4-Dihydroxyphenylalanine Administration in Parkinsonian Rats J. Neurosci., April 15, 1999; 19(8): 3266 - 3274. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Takahashi, L. L. Miner, I. Sora, H. Ujike, R. S. Revay, V. Kostic, V. Jackson-Lewis, S. Przedborski, and G. R. Uhl VMAT2 knockout mice: Heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity PNAS, September 2, 1997; 94(18): 9938 - 9943. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Parmer, M. Mahata, S. Mahata, M. T. Sebald, D. T. O'Connor, and L. A. Miles Tissue Plasminogen Activator (t-PA) Is Targeted to the Regulated Secretory Pathway. CATECHOLAMINE STORAGE VESICLES AS A RESERVOIR FOR THE RAPID RELEASE OF t-PA J. Biol. Chem., January 17, 1997; 272(3): 1976 - 1982. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Gualix, M. Abal, J. Pintor, F. Garcia-Carmona, and M. T. Miras-Portugal Nucleotide Vesicular Transporter of Bovine Chromaffin Granules J. Biol. Chem., January 26, 1996; 271(4): 1957 - 1965. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||